CD302

Across TCGA pan-cancer cohorts, CD302 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated CD302 data layer compared with 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD302 RNA is associated with better overall survival. In most high-consensus cancer types, elevated CD302 expression acts as an unfavorable survival marker, although some lineages such as LUAD and KIRC show a favorable association.

LUAD, KIRC, and LGG are the cancer types where CD302 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.868	0.753	<.001	109	view →
KIRC	DFS	Median	All	0.703	0.558	<.001	80	view →
LGG	OS	Median	All	0.734	0.893	<.001	54	view →
ACC	DFS	Median	III,IV	0.152	0.515	.002	49	view →
UVM	DFS	Quartile	III,IV	0.254	0.914	.003	47	view →
BRCA	DFS	Quartile	III,IV	0.940	0.787	.009	39	view →
STAD	OS	Median	All	0.626	0.824	.004	37	view →
HNSC	DFS	Quartile	IV	0.470	0.229	.002	25	view →
COAD	OS	Median	All	0.875	0.716	.005	23	view →
ESCA	OS	Median	IV	0.222	0.698	.006	12	view →
PRAD	DFS	Tertile	All	0.981	0.921	.001	12	view →
KICH	DFS	Median	II,III,IV	0.575	0.918	.005	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

CD302–LUAD (OS)

Open the LUAD breakdown →